Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development

Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now.

At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc. (NASDAQ:GANX) unveiled new preclinical data on its lead drug candidate, GT-02287.

GT-02287, a small molecule, focuses on treating Parkinson’s disease (PD) by restoring the function of glucocerebrosidase (GCase). GCase is an enzyme impaired in PD due to GBA1 mutations. Lysosomes and mitochondria, which are critical areas affected in PD, are targeted by the drug.

The drug’s ability to reduce mitochondrial stress and promote neuronal survival was highlighted in the new data through three separate preclinical models. Within a mouse model of PD, GT-02287 improved mitochondrial function, while in patient-derived cells, it enhanced mitochondrial function and GCase levels.

With these findings, Gain Therapeutics, Inc. (NASDAQ:GANX) demonstrated further evidence of the drug’s potential as a disease-modifying therapy for PD. The company also highlighted the possibility of slowing or stopping disease progression. Management remains confident that these preclinical results will translate into significant clinical benefits for patients.

Earlier, BTIG’s analyst Thomas Shrader expressed optimism about the drug’s progress so far and its potential to draw interest from potential partners. This confidence was evident in the analyst’s November 13 reiteration of a “Buy” rating on Gain Therapeutics, Inc. (NASDAQ:GANX).

Gain Therapeutics, Inc. (NASDAQ:GANX), a clinical-stage biotechnology company, focuses on developing therapies for Parkinson’s disease, neurodegenerative diseases, and other rare disorders.

READ NEXT: 12 Best Commodity Stocks to Buy Right Now and 10 Best Crypto-Related Stocks to Invest In.

Disclosure: None.